PolyPid Ltd. (PYPD) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• PolyPID (PYPD) Q4 2025: R&D Spend Falls 11% as DPLEX 100 Nears Regulatory Milestone
  June 15, 2026
• PolyPID (PYPD) Q1 2026: NDA Submission Nears Completion as $4.3M PDUFA Waiver Bolsters Runway
  May 13, 2026
• Polypid (PYPD) Q3 2025: 58% SSI Reduction Drives DPLEX-100 Launch Momentum and Partner Interest
  November 12, 2025
• PolyPid (PYPD) Q2 2025: DPLEX-100 Cuts Surgical Infection Rates by 58%, Unlocking U.S. Partner Leverage
  August 13, 2025

Browse all companies